# Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

Source: https://onco.cc/trials/nct07388524/  
OnCo record `nct07388524` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of atezolizumab in lung cancer, run by National Cancer Institute (NCI), now recruiting.

## Summary

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial is a phase 3, randomised interventional study registered as NCT07388524 by National Cancer Institute (NCI), with a registry enrolment figure of 336 participants, started 2027-03-02 and due to reach its primary completion in 2032-09-30. Interventions recorded: Atezolizumab; Atezolizumab and Recombinant Human Hyaluronidase; Biospecimen Collection; Computed Tomography; Patient Observation. Conditions listed: Lung Non-Small Cell Carcinoma. Primary outcome: Disease-free survival. Lung eligibility wording from the registry: "* Pathologically stage IA3 or IB NSCLC per American Joint Committee on Cancer (AJCC) Cancer Staging Manual, 9th edition". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07388524
- Phase: 3
- Setting: Evaluating Adjuvant Atezolizumab or Atezolizumab and Hyaluronidase-TQJS to Prevent Recurrence in Stage I Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase III Trial (AASI-NSCLC)
- Sponsor: National Cancer Institute (NCI)
- Enrolled: 336

## Sources

- ClinicalTrials.gov NCT07388524: https://clinicaltrials.gov/study/NCT07388524

## Connected records

- cancers: [Resectable stage I to III non-small-cell lung cancer](https://onco.cc/cancers/resectable-nsclc/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07388524.json